Epetraborole

Drug Profile

Epetraborole

Alternative Names: (S)-3-aminomethylbenzoxaborole; ABX; AN-3365; GSK '052; GSK-052; GSK-2251052

Latest Information Update: 26 Mar 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Anacor Pharmaceuticals
  • Developer Anacor Pharmaceuticals; GlaxoSmithKline
  • Class 2 ring heterocyclic compounds; Antibacterials; Benzene derivatives; Organic boron compounds; Small molecules
  • Mechanism of Action Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Gram-negative infections
  • Discontinued Intra-abdominal infections; Urinary tract infections

Most Recent Events

  • 21 Mar 2013 AN 3365 is no longer licensed to GlaxoSmithKline. Anacor is considering its options for further development of the compound, if any
  • 21 Mar 2013 Suspended - Phase-II for Gram-negative infections in USA (IV)
  • 05 Oct 2012 Discontinued - Phase-I for Gram-negative infections in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top